• English
    • íslenska
  • English 
    • English
    • íslenska
  • Login
View Item 
  •   Home
  • Journal Articles, Peer Reviewed (Ritrýndar vísindagreinar)
  • Icelandic Journal Articles (Peer Reviewed)
  • View Item
  •   Home
  • Journal Articles, Peer Reviewed (Ritrýndar vísindagreinar)
  • Icelandic Journal Articles (Peer Reviewed)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of HirslaCommunitiesAuthorsTitleSubjectsSubject (MeSH)Issue DateJournalThis CollectionAuthorsTitleSubjectsSubject (MeSH)Issue DateJournal

My Account

LoginRegister

Local Links

FAQ - (Icelandic)FAQ - (English)Hirsla LogosAbout LandspitaliLSH Home PageLibrary HomeIcelandic Journals

Statistics

Display statistics

Lyfjameðferð kransæðasjúklinga á Íslandi

  • CSV
  • RefMan
  • EndNote
  • BibTex
  • RefWorks
Thumbnail
Name:
L1999-06-85-F1.pdf
Size:
594.7Kb
Format:
PDF
Description:
Allur texti - Full text
Download
Average rating
 
   votes
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
 
Your vote was cast
Thank you for your feedback
Authors
Emil L. Sigurðsson
Jón Steinar Jónsson
Guðmundur Þorgeirsson
Issue Date
1999-06-01

Metadata
Show full item record
Other Titles
Medical treatment of coronary heart disease in Iceland
Citation
Læknablaðið 1999, 85(6):510-5
Abstract
Objective: During the last decades the knowledge of prevention of coronary heart disease (CHD) has increased dramatically. Results from large clinical trials on drug treatment of patients with CHD with various groups of drugs has given new possibilities to improve the prognosis of our patients. However, results from several studies have shown that this knowledge has not yet been put into practice. The main aim of our study, which is a part of a larger enquiry into the actual practice of secondary prevention of CHD in Iceland, was to evaluate the medical treatment of CHD, other than lipid lowering therapy. Material and methods: All patients with residence in Hafnarfjörður, Garðabær and Bessastaðahreppur who have been diagnosed as having CHD were sent a letter with an invitation to participate in the study and a request for an informed consent. Those who choose to participate responded to a questionnaire and gave a permission for a review of their records with respect to a specific diagnosis and lipid values. The patients were divided into four groups on the basis of their history: I. myocardial infarction (MI), II. coronary artery bypass surgery (CABG), III. percutaneous transiluminal coronary angioplasty (PTCA) and IV. angina pectoris (AP). If a patient fulfilled the critera for more than one diagnostic group the CABG group had the highest priority followed by PTCA, MI and finally AP. Results: A total of 533 patients with CHD were living in the study area and of those 402 (75%) participated in the study. Aspirin was used by 284 patients (71%), 75% among men and 65% among women (p=0.018). The highest proportion (91%) being among those who had undergone CABG, and the lowest among those with angina pectoris (56%). Half of the patients (52%) used beta blockers and 119 (30%) diuretics. A total of 172 patients received treatment with nitrates (43%), 57% of the women and 27% of the men (p=0.006). Calcium blockers were used by 145 patients (36%) and ACE inhibitors by 81 (20%). Among women in the age group 40 to 80 years, 16% were receiving hormone replacement therapy. Conclusions: These results indicate that in Iceland, as in many other countries, secondary prevention of CHD is not beeing fully implemented and the scientific evidence that has been obtained from large clinical trials, has not yet been put into practice. There is obviously a great potential to improve the medical treatment and prognosis of our patients with CHD.
Tilgangur: Á síðustu áratugum hefur þekkingu manna á forvörnum hjarta- og æðasjúkdóma fleygt fram. Niðurstöður stórra klínískra rannsókna á lyfjameðferð kransæðasjúklinga með ýmsum lyfjaflokkum hafa leitt af sér nýja möguleika til þess að hafa áhrif á horfur sjúklinga með kransæðasjúkdóm. Rannsóknir erlendis frá hafa þó sýnt að þessi þekking er enn ekki nýtt sem skyldi. Tilgangur þessarar rannsóknar, sem er hluti af stærri rannsókn á meðferð og eftirliti sjúklinga með kransæðasjúkdóm á íslandi, var að kanna hvernig lyfjameðferð kransæðasjúklinga, annarri en blóðfitulækkandi, er háttað á Íslandi Efniviður og aðferðir: Rannsóknarþýðið voru allir sjúklingar sem greinst hafa með kransæðasjúkdóm og búsettir voru í Hafnarfirði, Garðabæ og Bessastaðahreppi. Sjúkdómsgreining og aðrar heilsufarsupplýsingar voru fengnar úr sjúkraskýrslum Heilsugæslustöðvarinnar á Sólvangi annars vegar og Heilsugæslunnar í Garðabæ hins vegar. Sjúklingarnir fengu spurningalista um meðferð, eftirlit og þekkingu þeirra á helstu áhættuþáttum kransæðsjúkdóms. Sjúkraskýrslur þeirra sem svöruðu spurningalistanum voru skoðaðar og heilsufarsupplýsingar skráðar. Sjúklingum var skipt í eftirfarandi greiningarflokka: I. hjartadrep, II. farið í kransæðaaðgerð, III. farið í kransæðavíkkun og IV. með hjartaöng. Ef einhver þátttakandi gat tilheyrt fleiri en einum flokki var kransæðaaðgerð látin vega þyngst, síðan kransæðavíkkun, þá hjartadrep og loks hjartaöng. Niðurstöður: Alls voru 533 einstaklingar með kransæðasjúkdóm á rannsóknarsvæðinu og af þeim tóku 402 (75%) þátt í þessari rannsókn. Asetýlsalisýlsýru notuðu 284 sjúklingar (71%), 75% karla og 63% kvenna (p=0,018). Hæsta meðferðarhlutfallið (91%) var meðal þeirra sem farið höfðu í kransæðaaðgerð en lægst hjá þeim sem höfðu hjartaöng (56%). Rúmlega helmingur sjúklinganna (52%) notaði beta-blokkara og 119 þvagræsilyf (30%). Alls notuðu 172 sjúklingar nítröt (43%), hlutfallslega fleiri konur notuðu nítröt en karlar, 57% á móti 27% (p=0,006). Kalsíumblokkara notuðu 145 (36%) og ACE-hamlara (angiotensin con-verting enzyme inhibitors) 81 (20%). Af konum á aldursbilinu 40-80 ára voru 16% á hormónameðferð. Ályktanir: Niðurstöður þessarar rannsóknar benda til þess að hér á landi, líkt og í fjölmörgum öðrum löndum, sé annars stigs forvörnum hjarta- og æðasjúkdóma ábótavant og sú þekking sem aflað hefur verið með stórum klínískum rannsóknum varðandi lyfjameðferð þessa sjúklingahóps, ekki nýtt nægilega vel. Því er ljóst að umtalsverðir möguleikar eru til að bæta meðferð og horfur kransæðasjúklinga.
Description
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open
Additional Links
http://www.laeknabladid.is
Collections
Icelandic Journal Articles (Peer Reviewed)

entitlement

 

DSpace software (copyright © 2002 - 2021)  DuraSpace
Quick Guide | Contact Us
Open Repository is a service operated by 
Atmire NV
 

Export search results

The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.